JP2019534317A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534317A5
JP2019534317A5 JP2019533260A JP2019533260A JP2019534317A5 JP 2019534317 A5 JP2019534317 A5 JP 2019534317A5 JP 2019533260 A JP2019533260 A JP 2019533260A JP 2019533260 A JP2019533260 A JP 2019533260A JP 2019534317 A5 JP2019534317 A5 JP 2019534317A5
Authority
JP
Japan
Prior art keywords
isolated
amino acid
purified
proteinaceous molecule
lsd1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533260A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534317A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2017/050969 external-priority patent/WO2018045422A1/en
Publication of JP2019534317A publication Critical patent/JP2019534317A/ja
Publication of JP2019534317A5 publication Critical patent/JP2019534317A5/ja
Pending legal-status Critical Current

Links

JP2019533260A 2016-09-07 2017-09-07 リジン特異的ヒストンデメチラーゼ−1阻害剤及びその使用 Pending JP2019534317A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903602A AU2016903602A0 (en) 2016-09-07 Inhibitors and uses therefor
AU2016903602 2016-09-07
PCT/AU2017/050969 WO2018045422A1 (en) 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor

Publications (2)

Publication Number Publication Date
JP2019534317A JP2019534317A (ja) 2019-11-28
JP2019534317A5 true JP2019534317A5 (cg-RX-API-DMAC10.html) 2021-03-04

Family

ID=61561256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533260A Pending JP2019534317A (ja) 2016-09-07 2017-09-07 リジン特異的ヒストンデメチラーゼ−1阻害剤及びその使用

Country Status (8)

Country Link
US (1) US20220040280A1 (cg-RX-API-DMAC10.html)
EP (1) EP3509627A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019534317A (cg-RX-API-DMAC10.html)
CN (1) CN110312522A (cg-RX-API-DMAC10.html)
AU (1) AU2017323868A1 (cg-RX-API-DMAC10.html)
CA (1) CA3035806A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201901624RA (cg-RX-API-DMAC10.html)
WO (1) WO2018045422A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102095104B1 (ko) * 2018-04-24 2020-04-23 서울대학교산학협력단 PKCα-LSD1-NFκB 경로를 표적으로 하는 염증반응 조절제 스크리닝 방법용도
EP3636284A1 (en) * 2018-10-11 2020-04-15 NBE Therapeutics AG Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
CN110142068B (zh) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法
CA3149964A1 (en) * 2019-09-03 2021-03-11 Michelle Wykes Methods and agents for determining patient status
CN112326961B (zh) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备
EP4419093A1 (en) * 2021-10-20 2024-08-28 Queen Mary University of London Sequential treatments and biomarkers to reverse resistance to kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741086B2 (en) * 2004-12-16 2010-06-22 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
WO2007006581A2 (en) * 2005-07-13 2007-01-18 Universitätsklinikum Freiburg Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US20120108500A1 (en) * 2010-10-07 2012-05-03 Naoki Sakane Compositions and Methods for Modulating Immunodeficiency Virus Transcription
EP3789405A1 (en) * 2012-10-12 2021-03-10 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
SG11201510369WA (en) * 2013-06-25 2016-01-28 Univ Canberra Methods and compositions for modulating cancer stem cells
US9186391B2 (en) * 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
AU2015309686B2 (en) * 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
KR20180099768A (ko) * 2015-12-30 2018-09-05 노파르티스 아게 증진된 효능을 갖는 면역 이펙터 세포 요법

Similar Documents

Publication Publication Date Title
Zhang et al. Human T-cell lymphotropic virus type 1 and its oncogenesis
Verhelst et al. Mx proteins: antiviral gatekeepers that restrain the uninvited
SG181523A1 (en) Therapeutic compounds and related methods of use
Vähä-Koskela et al. Tumor restrictions to oncolytic virus
Sang et al. Macrophage polarization in virus-host interactions
Ohkoshi et al. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy
EA027040B1 (ru) Модулирующие иммуносупрессию соединения
JP2016515561A5 (cg-RX-API-DMAC10.html)
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
CA2787309A1 (en) Hepatitis c virus inhibitors
Suprunenko et al. Complexities of type I interferon biology: Lessons from LCMV
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
JP2018023397A5 (cg-RX-API-DMAC10.html)
MX2024005883A (es) Compuesto para el secuestro de anticuerpos no deseables en un paciente.
CN101631780A (zh) 用于抗病毒治疗的吩噻嗪衍生物
Stott et al. Distinct molecular mechanisms of host immune response modulation by arenavirus NP and Z proteins
Lara-Urena et al. Relevance of BET family proteins in SARS-CoV-2 infection
RU2018142174A (ru) Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения
US7604804B2 (en) Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120
Jayaram et al. The virion N protein of infectious bronchitis virus is more phosphorylated than the N protein from infected cell lysates
JPWO2019031470A1 (ja) 新規アミド系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤
AU2018269937A1 (en) Methods for modifying endoplasmic reticulum processing of protein
JP2022533251A (ja) 患者において血清リン酸塩を低下させるための組み合わせ
JP2019505210A5 (cg-RX-API-DMAC10.html)
RU2018126487A (ru) Противораковые вакцины